Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azirkitug Monotherapy and Combinations in Advanced Solid Tumors
NCT05005403Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, open-label trial of ABBV-514 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and 5 more (17 arms), sponsored by AbbVie Inc. Primary endpoints: Adverse Events up to 2 Years, Maximum Observed Serum Concentration of Azirkitug up to 2 Years and 17 more. Started Nov 2021; status: recruiting.
02
Drugs
ABBV-514
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT05005403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005403.